When was Alebund founded?

Alebund was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Alebund located?

Alebund is headquartered in Shanghai, China.

Who is the current CEO of Alebund?

Gavin Xia of Alebund. They have also founded 1 company.

Is Alebund a funded company?

Alebund is a funded company, having raised a total of $114M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on 2020.

When was the latest funding round of Alebund?

Alebund's latest funding was a $***** Series B round on Sep 13, 2021, with participation from 11 investors.

Where does Alebund rank among its competitors?

Alebund ranks 3rd amongst 114 active competitors, of which 38 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Regenfro Co, which secured $7.56M in Jun, 2026.

Who are the top competitors of Alebund?

Alebund's top competitors include Akebia Therapeutics, Aurinia Pharmaceuticals and Renalys. Among them, Regenfro Co secured the most recent funding round in June, 2026.

Alebund - 2026 Company Profile, Team, Funding & Competitors

Alebund is a public company based in Shanghai (China), founded in 2018 by Gavin Xia and Jin Tian. It operates as a Developer of therapeutics for kidney diseases. Alebund has raised $114M in funding from investors like Morningside, Loayal Valley Capital and Quan Capital. The company has 114 active competitors, including 38 funded and 30 that have exited. Its top competitors include companies like Akebia Therapeutics, Aurinia Pharmaceuticals and Renalys.

Company Details

Developer of therapeutics for kidney diseases. The lead candidate AP-301 for the treatment of hyperphosphatemia, AP-303 for diabetic kidney disease, AP-304 for autosomal dominant polycystic kidney disease, AP-302, and AP-305 an antibody against the effector enzyme of the complements lectin pathway for IgA nephropathy.

Website: www.alebund.com
Email ID: *****@alebund.com

Key Metrics

Founded Year

2018

Location

Shanghai, China

Stage

Public

Total Funding

$114M in 3 rounds

Latest Funding Round

Series B, Sep 13, 2021, $*****

Investors

Morningside & 15 more

Ranked

3^rd among 114 active competitors

Similar Companies

Akebia Therapeutics & 127 more

Exit Details

Public

View Alebund's full profile

Alebund got listed on Jun 29, 2026.

Click here to take a look at Alebund's IPO in detail

Alebund has raised a total funding of $114M over 3 rounds. Its first funding round was on 2020. Its latest funding round was a Series B round on Sep 13, 2021 for $*****. 11 investors participated in its latest round. Alebund has 16 institutional investors.

Here is the list of recent funding rounds of Alebund:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 13, 2021	2434223	Series B	2348026	4684463	1804717	3811399
May 10, 2021	8974746	Series B	6197999	2141743	3774095	3E BioVentures & 3 more
2020	4771	Series A	7979	3729	Huagai Capital	7015

Access funding benchmarks and valuations. Sign up today!

View details of Alebund's funding rounds and investors

The founders of Alebund are Gavin Xia and Jin Tian. Gavin Xia is the CEO of Alebund.

Here are the details of Alebund's key team members:

Gavin Xia: Co-Founder & CEO of Alebund.
Jin Tian: Co-Founder of Alebund.
Contact Info: 1 email address

View details of Alebund's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Alebund include Akebia Therapeutics, Aurinia Pharmaceuticals and Renalys. Here is the list of Top 10 competitors of Alebund, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Akebia Therapeutics 2007, Cincinnati (United States), Public	Developing therapeutics solutions to treat patients with kidney disease	$91M	Genechem, Longitude Capital & 13 others	66/100
2nd	Aurinia Pharmaceuticals 1993, Edmonton (Canada), Public	Developer of therapeutics for autoimmune diseases	-	RA Capital Management, VenBio & 10 others	64/100
3rd	Alebund 2018, Shanghai (China), Public	Developer of therapeutics for kidney diseases	$114M	Verition Fund Management, Loayal Valley Capital ... & 14 others	63/100
4th	Renalys 2023, Chuo City (Japan), Acquired	Developer of therapeutics for the treatment of renal diseases	$38.2M	SR One, Catalys Pacific & 4 others	61/100
5th	Secretome Therapeutics 2018, Dallas (United States), Series A	Developer of cell-based therapies for multiple diseases	$52.2M	RA Capital Management, Parent Project Muscular Dystrophy ... & 2 others	61/100
6th	Enyo Pharma 2014, Lyon (France), Series C	Developer of therapeutics for diseases with impaired kidney function	$120M	Orbimed, Morningside & 9 others	60/100
7th	Arthrosi Therapeutics 2017, Irvine (United States), Acquired	Developer of therapeutics for gout, chronic kidney diseases, and oncology	$293M	Prime Eight Capital, Guangrun Health Industry ... & 11 others	60/100
8th	Calliditas Therapeutics 2004, Stockholm (Sweden), Public	Provider of small molecule based drug for inflammatory kidney disease	$44.8M	Investinor, Athyrium Capital Management & 3 others	58/100
9th	Purespring Therapeutics 2020, London (United Kingdom), Series B	Developer of therapeutics for chronic renal diseases	$164M	Syncona, Sofinnova Partners & 3 others	56/100
10th	Regenfro Co 2019, Kyoto (Japan), Series B	Developer of therapeutics to treat renal diseases	$36.4M	Mitsubishi UFJ Capital, Kyoto University Innovation Capital ... & 24 others	56/100